Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.13, 2013-09, pp. : 1711-1721

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bexarotene in combination with PUVA may be a treatment option in patients with cutaneous T-cell lymphoma refractory to multiple single-agent therapies

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Management of cutaneous T-cell lymphoma

By Duhovic Chris Child Fiona Wain E Mary

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Interferon (IFN)- plus bexarotene were effective in the treatment of multi focal, cutaneous, CD30+, large T cell lymphoma

Inpharma, Vol. 1, Iss. 1324, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Retrospective Cohort Study of Venlafaxine, Fluoxetine or Sertraline in Long-Term Care

By Blake L.M.

Clinical Drug Investigation, Vol. 23, Iss. 11, 2003-01 ,pp. : 735-742

Adis International

Access to resources Recommend Favorite

Efalizumab: Progression of cutaneous T-cell lymphoma: case report

Reactions Weekly, Vol. 1, Iss. 1238, 2009-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite